Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Podobne zapisy

• Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
  od: Ramirez, Krista G.
  Wydane: (2017)
• Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma
  od: Raedler, Lisa A.
  Wydane: (2016)
• Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
  od: Kumar, Shaji K., i wsp.
  Wydane: (2014)
• Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
  od: Richardson, Paul G., i wsp.
  Wydane: (2014)
• Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
  od: Gupta, Neeraj, i wsp.
  Wydane: (2017)